Protix is indicated for the management of chronic pain and associated inflammation stemming from long-term inflammatory conditions. The medication is used to help address the physical discomfort and swelling related to several common ailments, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

It is intended to assist in managing the frequency and severity of disease flare-ups, offering support for sustained wellness. By helping to mitigate symptoms like joint stiffness and restricted mobility, Protix may support patients' ability to perform daily activities with greater comfort.

“The medication helps me feel a greater sense of control over my day-to-day physical limitations.”

Quick Fact: Relief for Joint Stiffness Protix is formulated to help relieve the persistent joint stiffness that often accompanies inflammatory conditions, supporting improved range of motion.

Protix is restricted to adults and adolescents who are 12 years of age or older and weigh 35 kg or more. Use in children younger than 12 years or weighing less than 35 kg is generally considered not recommended or not established by regulatory bodies due to concerns regarding efficacy and cardiac safety.

The medicine is strictly contraindicated and must not be used by individuals with specific pre-existing conditions, primarily centered on cardiovascular risk. This includes known QTc prolongation, underlying cardiac diseases such as congestive heart failure, or significant electrolyte disturbances. Use is also strictly prohibited for patients with moderate or severe hepatic impairment, a prolactin-releasing pituitary tumour, or gastrointestinal hemorrhage, obstruction, or perforation. Furthermore, it is contraindicated for patients taking specific QTc-prolonging medicines or potent CYP3A4 inhibitors.

Conditional use is necessary for certain populations. Patients with severe renal impairment require a mandatory reduction in dosing frequency. For pregnant individuals, data is limited; use is permitted only if the expected benefit justifies the potential risk. Use is generally not recommended for lactating individuals, as the active substance is excreted in human milk.

Interactions with other medicines and products

Protix has officially documented interactions with other medicines due to its primary metabolic pathway and its effect on drug transport mechanisms. The regulatory information identifies that Protix is primarily broken down by the Cytochrome P450 3A4 (CYP3A4) enzyme and is also a substrate for the P-glycoprotein (P-gp) drug transporter.

Clinically Significant Interaction Categories

• Medicines that are Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors, such as Ketoconazole or Ritonavir, is generally not recommended/contraindicated. These medicines can significantly increase the concentration of Protix in the body.
• Medicines that are Strong CYP3A4 Inducers: Concomitant use with strong inducers, such as Rifampin, is also to be avoided as it significantly reduces Protix exposure, potentially diminishing its effect. A specific time period must pass after stopping the inducer before Protix administration.
• Medicines that are P-gp Substrates: Protix may inhibit the P-gp transporter, leading to increased exposure of co-administered medicines that rely on this transporter (e.g., Digoxin).
• Dietary Products: Consumption of grapefruit or grapefruit juice can also increase the exposure of Protix and should be avoided.

These restrictions are based on pharmacokinetic studies documented in official government labeling, which describe the magnitude of the concentration change when these specific interaction partners are used together.

How Protix Works: Mechanism of Action

Protix (Domperidone) primarily acts by selectively blocking dopamine D2 receptors in the peripheral nervous system. This mechanistic action occurs in two principal physiological domains.

Firstly, D2 receptor antagonism in the Chemoreceptor Trigger Zone (CTZ)—an area outside the blood-brain barrier—suppresses the initiation of the emetic reflex cascade by blocking chemical signals. The drug's minimal penetration of the central nervous system ensures a predominantly peripheral effect.

Secondly, D2 antagonism in the smooth muscle of the upper gastrointestinal tract removes the normal inhibitory effect of dopamine on motility. This disinhibition enhances the local release of acetylcholine and stimulates muscle contractions. This sequence produces the physiological effects of accelerated gastric emptying and increased lower esophageal sphincter tone. As a mechanistic consequence of broad peripheral D2 antagonism, blockade of receptors in the anterior pituitary gland removes the inhibition of prolactin, leading to an elevation in circulating prolactin levels.

Protix is available for administration via the oral and rectal routes, with approved dosage forms including tablets, oral suspension, oral drops, and suppositories. The selection of the route dictates the administration strength and maximum daily limit. Oral doses are typically 10 mg per dose, while rectal suppositories are 30 mg per dose. The maximum daily dose for oral administration must not exceed 30 mg total, and for rectal administration, the maximum is 60 mg.

The dosing schedule mandates that the medicine is taken up to three times per day (oral) or two times per day (rectal), with a critical minimum interval of approximately eight hours between doses. A core requirement for proper use is taking the dose before meals, ideally 15 to 30 minutes prior.

The use of Protix is officially constrained to the lowest effective dose for the shortest duration necessary, and treatment must not exceed a maximum of seven consecutive days.

Specific procedural requirements apply: tablets must be swallowed whole and not crushed, and liquid formulations must be measured with an accurate device to ensure precision. If a dose is missed, the patient is directed to simply omit the missed dose and resume the usual schedule; under no circumstances should the dose be doubled. For special populations, adjustments are necessary: patients with severe renal impairment require a reduction in dosing frequency, and standard tablet/suppository forms are generally reserved for individuals weighing 35 kg or more.

Research Evidence / Overview of Studies for Protix

---

Evidence for Short-Term Relief of Nausea and Vomiting

Research for this indication primarily involved short-term Randomized Controlled Trials (RCTs) and meta-analyses, which are study designs used in research exploring how symptoms change over time. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as acute sickness. The studies included populations of adults and adolescents who met specific age and weight criteria.

The outcomes research examined symptom axes related to episodic or acute changes, such as vomiting frequency and nausea severity, using standardized scales. Studies report how symptoms evolved in the observed populations during the defined, short time intervals of the research. Findings describe patterns observed in the trials relevant in evidence describing how symptoms are measured.

Regulatory reviews have noted that data for children under 12 years with acute sickness symptoms remain insufficient, and in some research, findings were mixed compared to placebo. The evidence reflects the specific conditions under which the studies were conducted, meaning that insights are primarily limited to research exploring short-term symptom changes related to acute episodes.

---

Evidence for Symptoms of Diabetic Gastroparesis

The evidence base for this condition, characterized by functional limitations, comes from Placebo-Controlled Withdrawal Trials and long-term observational settings that were used in research exploring how symptoms change over time. The studies included populations of adults with diabetes and clinically confirmed delayed gastric emptying.

The research examined outcomes related to systemic or functional imbalance, monitoring scores related to perceived discomfort (e.g., the Gastroparesis Cardinal Symptom Index or GCSI). Studies also examined outcomes reflecting daily functioning or activity level using Quality of Life assessments. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience with chronic symptoms.

---

Understanding Uncertainty and Research Gaps

For some research protocols, the sample sizes were modest, meaning the results describe group patterns, but research does not determine whether an individual will respond similarly. Evidence is limited for the long-term consistency of findings for conditions marked by functional limitations. Findings were mixed or inconsistent in some studies related to broader chronic GI disorders. The overall level of evidence for long-term effects or for applications outside of the specific indications remains to be fully established by research.

Common questions about Protix (FAQ)

Q: Is this medicine safe for women who are pregnant or breastfeeding?

Official regulatory documents indicate that Protix is not recommended during pregnancy, especially after the first three months. Regulatory documents indicate potential risks to the developing fetus associated with use during the second and third trimesters. For breastfeeding, use is generally not recommended for newborns or infants who were born prematurely. For older infants, the official information suggests that alternative medicines are often preferred, but use may be discussed with a healthcare provider.

Q: Is it safe long-term?

According to the official product information, Protix is approved for the long-term treatment of conditions such as high blood pressure, heart failure, and post-heart attack management. Regulatory information indicates that long-term use requires periodic monitoring of blood pressure, kidney function, and blood potassium levels to ensure appropriate continuation of treatment.

Q: Can children 2 years old use it?

Regulatory sources state that Protix is not recommended for the treatment of high blood pressure in children under 6 years of age. It is also not recommended for children who have severe kidney function issues. The official documentation specifies eligibility criteria for children, primarily related to age and the presence of certain health conditions.

How to Store and Dispose of Protix?

Protix (Domperidone) must be stored according to regulatory requirements to maintain its stability.

---

Storage Conditions

Item	Requirement
Temperature	Store below 25 C (77 F); liquid forms must not exceed 30 C (86 F).
Freezing	Do not freeze the product.
Container	Keep in the original container and keep liquid bottles tightly closed.
Stability	The oral suspension/drops must be discarded six months after the first opening.
Safety	Keep this medicine out of the sight and reach of children.

---

Disposal Instructions

Do not throw away unused or expired Protix in household trash or via wastewater. For environmental safety, the medicine must be returned to a pharmacy or utilized in a local medicine collection program for proper disposal.